CYP19A1 and breast carcinoma: Furthermore, the only targeted therapies currently used in the management of breast cancer are directed at these receptors; ER-positive tumours are treated with endocrine therapy in the form of selective ER modulators, pure anti-oestrogens such as fulvestrant that completely inhibits ER signalling, or aromatase inhibitors that deplete extragonadal oestrogen synthesis.